VRAX Gunggung Aset Perusahaan Virax Biolabs Group Limited

The price action of Virax Biolabs Group (VRAX) total assets on GURU.Markets, which reached 7.37, confirms the business's resilience to economic downturns due to consistent demand for virus screening. Virax Biolabs Group (VRAX) aims for dominance in T-cell monitoring by promoting personalized ViraxClear tests. A steady cash flow from the sale of diagnostic panels allows the firm to fully fund its own R&D and maintain liquidity.

Total Aset Perusahaan: Virax Biolabs Group Limited (VRAX) kanggo 28.04.2023 - 31.10.2026

Rincian analitis lan laporan data perusahaan Virax Biolabs Group Ltd (VRAX)

- kuotasi lan prakiraan analis:

Kurs saham viraxbiolabs.com|VRAX - Bagan rega target

- data kapitalisasi pasar:

Biji pasar Virax Biolabs Corp|VRAX - Nilai Perusahaan

- rincian nilai buku perusahaan:

Nilai Aset Bersih saben Saham Virax Biolabs|VRAX - Kapitalisasi Buku|Rasio Kapitalisasi marang Nilai Buku viraxbiolabs.com|VRAX - Total Aset Perusahaan

- indikator beban utang lan likuiditas:

Total Utang marang Modal Virax Biolabs Group|VRAX - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Virax Biolabs Corp|VRAX - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Virax Biolabs Corp|VRAX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Virax Biolabs|Likuiditas darurat viraxbiolabs.com

- indikator profitabilitas perusahaan lan kelipatan valuasi:

VRAX - Bathi resik perusahaan

Pambiji fundamental:Virax Biolabs Group

The efficient organization of express biomaterial delivery and the control of reagent supply chains at Virax Biolabs Group (VRAX) directly impact the total asset value, which is reverse-calculated via daily ROA to identify hidden balance sheet changes. This indicator consolidates all company resources and liabilities, allowing investors to assess the scale of the operational base and the fundamental stability of the asset's price action.

Pesaing utama